Bibliography

105

1. Ali ZY. 2012. Biochemical Evaluation of Some Natural Products against Toxicity

Induced By Anti-tubercular Drugs in Rats. New York Sci J. 5(10) 69-80.

2. Alisjahbana B, van Crevel R, Sahiratmadja E, den Heijer M, Maya A, Istriana E, et

al. 2006. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int

J Tuberc Lung Dis. 10: 696-700.

3. Allocati N, Federici L, Masulli M, Di Ilio C. 2009. Glutathione transferases in

bacteria. FEBS J. 276: 58-75.

4. Ambreen K, Sharma R, Singh KP, Abbas M, Kumar S. 2014. Association of

GSTM1, GSTT1 and CYP2E1 Gene Polymorphisms with Antituberculosis Drug

Induced Hepatotoxicity in North Indian Population. Int J of Health Sciences &

Research. 4 (2): 149-160.

5. Andreyev AY, Kushnareva YE, Starkov AA. 2005. Mitrochondrial metabolism of

reactive oxygen species. Biochemistry. 70: 200-214.

6. Attri S, Rana SV, Vaiphei K, Sodhi CP, Katyal R, Goel RC, et al. 2000. Isoniazid-

and rifampicin-induced oxidative hepatic injury–protection by N-acetylcysteine.

Hum Exp Toxicol. 19: 517-524.

7. Attri S, Rana SV, Vaiphie K, Katyal R, Sodhi CP, Kanwar S, et al. 2001. Protective

effect of N-acetylcysteine in isoniazid induced hepatic injury in growing rats. Indian

J Exp Biol. 39: 436-440.

8. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al.

1994. inhA, a gene encoding a target for isoniazid and ethionamide in

Mycobacterium tuberculosis. Science. 263(5144): 227-230.

9. Barber DA, Harris SR. 1994. Oxygen free radicals and antioxidants: A review. Am

Pharm. 34: 26-35.

Bibliography

106

10. Bass JB, Farer LS, Hopewell PC, O’Brien R, Jacobs RF, Ruben F, et al. 1994.

Treatment of tuberculosis and tuberculosis infections in adults and children. Am J

Respir Crit Care Med. 149: 1359-1374.

11. Belanger AE, Besra GS, Ford ME, Mikusova K, Belisle JT, Brennan PJ, et al. 1996.

The embAB genes of Mycobacterium avium encode an arabinosyl transferase

involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial

drug ethambutol. Proc Natl Acad Sci USA. 93: 11919-11924.

12. Benichou C. 1990. Criteria of drug-induced liver disorders. Report of an

international consensus meeting. J Hepatol. 11: 272-276.

13. Beutler E, Duron O, Kelly BM. 1963. Improved method for the determination of

blood glutathione. J Lab Clin Med. 61: 882-888.

14. Bekierkunst A. 1966. Nicotinamide-adenine dinucleotide in tubercle bacilli exposed

to isoniazid. Science. 152(721): 525-526.

15. Bolt HM, Thier R. 2006. Relevence of the deletion polymorphisms of glutathione S-

tansferase GSTT1 and GSTM1 in pharmacology and toxicology. Current Drug

Metabolism. 7: 613-628.

16. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. 2006.

Adverse events and treatment interruption in tuberculosis patients with and without

HIV co-infection. Thorax. 61: 791-794.

17. Brennan PJ, Rooney SA, Winder FG. 1970. The lipids of Mycobacterium

tuberculosis BCG: fractionation, composition, turnover and the effects of isoniazid.

Ir J Med Sci. 3(8): 371-390.

18. Brewer TF, Heymann SJ. 2004. To control and beyond: moving towards eliminating

the global tuberculosis threat. J Epidemiol Community Health. 58: 822-825.

Bibliography

107

19. Cai Y, Yi J, Zhou C, Shen X. 2012. Pharmacogenetic Study of Drug-Metabolising

Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver

Injury: A Meta-Analysis. PLoS ONE. 7(10).

20. Calvert GM, Rice FL, Boiano JM, Sheehy JW, Sanderson WT. 2003. Occupational

silica exposure and risk of various diseases: an analysis using death certificates from

27 states of the United States. Occup Environ Med. 60(2): 122-129.

21. Calvori C, Frontali L, Leonil L, Tecce G. 1965. Effect of rifampicin on protein

synthesis. Nature. 207: 417-418.

22. Cegielski JP, McMurray DN. 2004. The relationship between malnutrition and

tuberculosis: evidence from studies in humans and experimental animals. Int J

Tuberc Lung Dis. 8(3): 286-298.

23. Chan J, Tanaka KE, Mannion C, Carroll D, Tsang MS, Xing Y, et al. 1997. Effects

of protein calorie malnutrition on mice infected with BCG. J Nutritional

Immunology. 5: 11-19.

24. Chakraborty AK. 2004. Epidemiology of tuberculosis: Current status in India.

Indian J Med Res. 120: 248-276.

25. Chatterjee S, Lyle N, Mandal A, Kundu S. 2010. GSTT1 and GSTM1 gene deletions

are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm

Ther. 35: 465-470.

26. Chen GX, Burnett CA, Cameron LL, Alterman T, Lalich NR, Tanaka S, et al. 1997.

Tuberculosis mortality and silica exposure: a case–control study based on a national

mortality database for the years 1983–1992. Int J Occup Environ Health. 3(3): 163-

170.

27. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW, et al. 2007. Genetic

polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced

Bibliography

108

hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis. 87:

551-556.

28. Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK. 2006.

Mitochondrial oxidative stress and permeability transition in isoniazid and

rifampicin induced liver injury in mice. J Hepatol. 45: 117-126.

29. Chowdhury A, Santra A, Kundu S, Mukherjee A, Pandit A, Chaudhuri S, et al.

2001. Induction of oxidative stress in antitubercular drug induced hepatotoxicity.

Indian J Gastroenteral. 20: 97-100.

30. Cillo U, Bassanello M, Vitale A, D’Antiga L, Zanus G, Brolese A, et al. 2005.

Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver’s

early regeneration after auxiliary partial orthotopic liver transplant. Transpl Int. 17:

713-771.

31. Combs DL, O’Brien RJ, Geiter LJ. 1990. USPHS tuberculosis shortcourse

chemotherapy trial 21: Effectiveness, toxicity and acceptability. The report of final

results. Ann Intern Med. 112(6): 397-406.

32. Comporti M, Saccocci C, Dianzani MU. 1965. Effect of CCl-4 in vitro and in vivo

on lipid peroxidation of rat liver homogenates and subcellular fractions.

Enzymologia. 29: 185-204.

33. Corbett EL, Bandason T, Cheung TB, Munyati S, Godfrey-Faussett P, Hayes R, et

al. 2007. Epidemiology of Tuberculosis in a High HIV Prevalence Population

Provided with Enhanced Diagnosis of Symptomatic Disease. 4 (1): 164-172.

34. Davies J, Gorini L, Davis B. 1965. Misreading of RNA codewords induced by

aminoglycoside antibiotics. Mol Pharmacol. 1: 93-106.

35. de Vries S. 1986. The pathway of electron transfer in the dimeric QH2: cytochrome

coxidoreductase. J Bioenerg Biomembr. 18: 195-224.

Bibliography

109

36. Desta Z, Soukhova NV, Flockhart DA. 2001. Inhibition of cytochrome P450

(CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Antimicrob Agents Chemother. 45: 382-392.

37. Dolin PJ, Raviglione MC, Kochi A. 1993. A review of current epidemiological data

and estimations of current and future incidence and mortality from tuberculosis.

Geneva: World Health Organization, Tuberculosis Program (in press).

38. Gerald L Mandell, John E, Bennett, Dollin R. 2010. Mandell, Douglas, and

Bennettt’s principles and practice of infectious disease. Churchill Livingstone

publisher ed. 7th; pp 1-4320.

39. Douglas KT. 1987. Mechanism of action of glutathione-dependent enzymes. Adv

Enzymol Relat Areas Mol Biol. 59: 103-167.

40. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. 2000. Diagnosis and

monitoring of hepatic injury: I. Performance characteristics of laboratory tests. Clin

Chem. 46: 2027-2049.

41. Ekstrom T, Hogberg J. 1980. Chloroform-induced glutathione depletion and

toxicity in freshly isolated hepatocytes. Biochem Pharmacol. 29: 3059-3065.

42. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al.

2000. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment

outcomes in 6 countries. J Am Med Assoc. 283: 2537-2545.

43. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. 2001.

Global trends in resistance to antituberculosis drugs. World Health Organization-

International Union against Tuberculosis and Lung Disease Working Group on Anti-

Tuberculosis Drug Resistance Surveillance. N Engl J Med. 344: 1294-1303.

44. Farrell GC. 1994. Drug-induced acute hepatitis. In: Farrell GC, ed. Drug-induced

liver disease. Edinburgh: Churchill Livingstone. 247-299.

Bibliography

110

45. Ferebee S, Mount F. 1969. Tuberculosis morbidity in a controlled trial of the

prophylactic use of isoniazid among household contacts. Am Rev Respir Dis.

85:490-510.

46. Fernandez-Villar A, Sopena B, Fernandez-Villar J, Vazquez-Gallardo R, Ulloa

F, Leiro V, et al. 2004. The influence of risk factors on the severity of anti-

tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 8: 1499-1505.

47. Fountain FF, Tolley E, Chrisman CR, Self TH. 2005. Isoniazid hepatotoxicity

associated with treatment of latent tuberculosis infection: a 7-year evaluation from a

public health tuberculosis clinic. Chest. 128: 116-123.

48. Fridovich I. 1995. Superoxide radical and superoxide dismutases. Annu Rev

Biochem. 64: 97-112.

49. Gangadharam PR, Harold FM, Schaefer WB. 1963. Selective inhibition of nucleic

acid synthesis in Mycobacterium tuberculosis by isoniazid. Nature. 198: 712-714.

50. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, et al.

2001. Metabolic gene polymorphism frequencies in control populations. Cancer

Epidemiol Biomarkers Prev. 10: 1239-1248.

51. Gholami K, Kamali E, Hajiabdolbagh Mi, Shalviri G. 2006. Evaluation of anti-

tuberculosis induced adverse reactions in hospitalized patients. Pharmacy Practice.

4: 134-138.

52. Ginsberg G, Smolenski S, Hattis D, Guyton KZ, Johns DO, Sonawane B, et al.

2009. Genetic Polymorphism in Glutathione Transferases (GST): Population

distribution of GSTM1, T1, and P1 conjugating activity. J Toxicol Environ Health B

Crit Rev. 12(5-6): 389-439.

53. Goasduff T, Bellec G, Amet Y, Dreano Y, Menez JF, Berthou F. 1996. P450 2E1

expression in liver, kidney, and lung of rats treated with single or combined

inducers. Alcohol. 13: 301-308.

Bibliography

111

54. Golden MP, Vikram HR. 2005. Extrapulmonary tuberculosis: an overview. Am Fam

Physician. 72(9): 1761-1768.

55. Guengerich FP, Kim DH, Iwasaki M. 1991. Role of human cytochrome P-450 IIE1

in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol.

4: 168-179.

56. Guengerich FP, Shimada T. 1998. Activation of procarcinogens by human

cytochrome P450 enzymes. Mutat Res. 400: 201-213.

57. Halliwell B, Gutteridge JM, Cross CE. 1992. Free radicals, antioxidants, and human

disease:where are we now? J Lab Clin Med. 119: 598-620.

58. Hayes JD, Flanagan JU, Jowsey IR. 2005. Glutathione transferases. Annu Rev

Pharmacol Toxicol. 45: 51-88.

59. Heifets L, Desmond E. 2005. Clinical mycobacteriology laboratory. In: Cole S,

Eisenach K, McMurray D, Jacobs W Jr, eds. Tuberculosis and the tubercle bacillus.

Washington DC, USA: ASM Press. 49-70.

60. Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y, et al. 2007.

NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker

for risk of antituberculosis drug-induced hepatotoxicity in Japanese patients with

tuberculosis. World J Gastroenterol. 13: 6003-6008.

61. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, et al. 2002. Polymorphism

of the N-acetyltransferase 2 gene as a susceptibility risk factor for all

antituberculosis drugs-induced hepatitis. Hepatology. 35: 883-889.

62. Huang YS, Su WJ, Huang YH. 2007. Genetic polymoprphism of manganese

dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and

T1, and susceptibility to drug-induced liver injury. J Hepatol. 47: 128-134.

Bibliography

112

63. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. 2003.

Cytochrome P4502E1 genotype and the susceptibility to antituberculosis drug-

induced hepatitis. Hepatology. 37: 924-930.

64. Hussain Z, Kar P, Hussain SA. 2003. Antituberculosis drug-induced hepatitis; risk

factors, prevention and manage-ment. Indian J Exp Biol. 41: 1226-1232.

65. Hwang S J, Wu J C, Lee C N, Yen FS, Lu CL, Lin TP, et al. 1997. A prospective

clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area

endemic for hepatitis B. J Gastroenterol Hepatol. 12: 87-91.

66. Ingelman-Sundberg M, Johansson I, Yin H, Terelius Y, Eliasson E, Clot P, et al.

1993. Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation,

and possible role in the etiology of alcohol-induced liver disease. Alcohol. 10: 447-

452.

67. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D Lemasters JJ. 2002.

Mechanisms of hepatotoxicity. Toxicol Sci. 65(2): 166-176.

68. Jenner AM, Timbrell JA. 1994. Influence of inducers and inhibitors of cytochrome

P450 on the hepatotoxicity of hydrazine in vivo. Arch Toxicol. 68: 349-357.

69. Jenner AM, Timbrell JA. 1995. In vitro microsomal metabolism of hydrazine.

Xenobiotica. 25: 599-609.

70. Jeon CY, Murray MB. 2008. Diabetes Mellitus Increases the Risk of Active

Tuberculosis: A Systematic Review of 13 Observational Studies PLoS Med. 5(7):

1091-1101.

71. Jezek P, Hlavata L. 2005. Mitochondria in homeostasis of reactive oxygen species in

cell, tissues, and organism. Int J Biochem Cell Biol. 37: 2478-2503.

Bibliography

113

72. Jindal SK. 2011. Textbook of Pulmonary and Critical Care Medicine. Edt. Shankar

PS, Suhail Raoof, Dheeraj Gupta, AN Aggarwal. Jaypee Brothers Medical

Publishers. Ed. Ist; pp. 1-2248.

73. Kent PT, Kubica GPW. 1985. Public Health Mycobacteriology. A guide for the level

III Laboratory. Atlanta: Centers for Disease Control. 21-44.

74. Koju D, Rao BS, Shrestha B, Shakya R, Makaju R. 2005. Occurance of side effects

from anti-tuberculosis drug in urban Nepalese population under DOTs treatment.

Kathmandu Univ J Sci Eng Technol. 1: 1-8.

75. Kopanoff DE, Snider DE, Caras GJ. 1978. Isoniazid-related hepatitis. Am Rev Respir

Dis. 117: 991-1001.

76. Kwara A, Flanigan TP, Carter EJ. 2005. Highly active antiretroviral therapy

(HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis. 9: 248-

257.

77. Lobato MN, Jereb JA, Starke JR. 2008. Unintended consequences: mandatory

tuberculin skin testing and severe isoniazid hepatotoxicity. Pediatrics. 121: 1732-

1733.

78. Landi S. 2000. Mammalian class theta GST and differential susceptibility to

carcinogens: a review. Mutat Res. 463: 247-283.

79. Lawn SD, Zumla AI. 2011. Tuberculosis. Lancet. 378 (9785): 57-72.

80. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, et al. 2005. Inactive

hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis

chemotherapy. Chest. 127: 1304-1311.

81. Lee BL, Wong D, Benowitz NL, Sullam PM. 1993. Altered patterns of drug

metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol

Ther. 53: 529-535.

Bibliography

114

82. Lee SW, Chung LSC, Huang HH, Chuang TY, Liou YH, Wu LSH. 2010. NAT2 and

CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-

induced hepatitis. Int J Tuberc Lung Dis. 14(5): 622-626.

83. Lee WM. 2003. Medical progress: drug-induced hepatotoxicity. N Engl J Med. 349:

474-485.

84. Leiro V, Fernandez-Villar A, Valverde D, Constenla L, Vazquez R, Pineiro L, et al.

2008. Influence of glutathione S-transferase M1 and T1 homozygous null mutations

on the risk of antituberculosis drug–induced hepatotoxicity in a Caucasian

population. Liver International. 28: 835-839.

85. Lewis DF, Bird MG, Parke DV. 1997. Molecular modelling of CYP2E1 enzymes

from rat, mouse and man: an explanation for species differences in butadiene

metabolism and potential carcinogenicity, and rationalization of CYP2E substrate

specificity. Toxicology. 118: 93-113.

86. Lo HW, Ali-Osman F. 2007. Genetic polymorphism and function of glutathione S-

transferases in tumor drug resistance. Curr Opin Pharmacol. 7: 367-374.

87. LoBue PA, Moser KS. 2005. Isoniazid- and rifampin-resistant tuberculosis in San

Diego County, California, United States, 1993–2002. Int J Tuberc Lung Dis. 9: 501-

506.

88. Maezawa Y, Yamauchi M, Toda G. 1994. Association between restriction fragment

length polymorphism of the human cytochrome p450IIE1 gene and susceptibility to

alcoholic liver cirrhosis. Am J Gastroenterol. 89: 561-565.

89. Maffei FR, Carini M. 1980. The inhibitory effect of pyrazinamide on microsomal

monooxygenase activities is related to the binding to reduced cytochrome P-450.

Pharmacol Res Commun. 12: 523-537.

Bibliography

115

90. Mahmood K, Hussain A, Jairamani KL, Talib A, Abbasi B, Salkeen S. 2007.

Hepatotoxicity with antituberculosis drugs: the risk factors. Pak J Med Sci. 23: 33-

38.

91. Makhlouf HA, Helmy A, Fawzy E, El-Attar M, Rashed HA. 2008. A prospective

study of antituberculosis drug-induced hepatotoxicity in an area endemic for liver

diseases. Hepatol Int. 2: 353-360.

92. Mandai AK, Das N. 2005. Sugar coated liposomal flavonoid: A unique formulation

in combating carbon tetrachloride induced hepatic oxidative damage. J Drug Target.

13: 305-315.

93. Marvin W. 1998. Impacts of gender on drug responses. Drug Top. 591-600. 94. Marzuki OA, Fauzi A R M, Ayoub S, Kamarul Imran M. 2008. Prevalence and risk

factors of antituberculosis drug-induced hepatitis in Malaysia. Singapore Med

Original Article J. 49(9): 688-693.

95. Masubuchi Y, Bourdi M, Reilly TP, Graf ML, George JW, Pohl LR. 2003. Role of

interleukin-6 in hepatic heat shock protein expression and protection against

acetaminophen-induced liver disease. Bio Chem Bio Phys Res Commun. 304: 207-

212.

96. McCord JM, Fridovich I. 1969. Superoxide dismutase. An enzyme functions of

erythrocuprein (hemocuprein). J Bio chem. 44: 6049-6055.

97. Mehta S. 1990. Malnutrition and drugs: clinical implications. Dev Pharmacol Ther.

15:159-165.

98. Mikusov K, Slayden RA, Besra GS, Brennan PJ. 1995. Biogenesis of the

mycobacterial cell wall and the site of action of ethambutol. A ntimicrob Agents

Chemother. 39: 2484-2489.

Bibliography

116

99. Miller SA, Dykes DD, Polesky HF. 1988. Simple salting out procedure for

extracting DNA from human nucleated cells. Nuclic Acids Res. 16: 1215.

100. Mitchison DA. 1985. The action of anti-tuberculosis drugs in short course

chemotherapy. Tubercle. 66: 219-225.

101. Mitchell JR, Snodgrass WR, Gillette JR. 1976. The role of biotransformation in

chemical-induced liver injury. Environ Health Perspect. 15: 27-38.

102. Todar K. 2009. Mycobacterium tuberculosis. Online textbook of Bacteriology. pp 1-

4.

103. Narasimhan P, Wood J, Maclntyre CR, Mathai D. 2013. Risk factor for

Tuberculosis. Pulmonary Medicine. http;//dx.doi.org/10.1155/2013/828939 1-11.

104. Nakajima T, Aoyama T. 2000. Polymorphism of drug-metabolizing enzymes in

relation to individual susceptibility to industrial chemicals. Ind Health. 38: 143-152.

105. Nasrullah M, Mazurek JM, Wood JM, Bang KM, Kreiss K. 2011. Silicosis Mortality

With Respiratory Tuberculosis in the United States, 1968–2006. Am J Epidemiol. 1-

10.

106. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB. 1976. Isoniazid

and iproniazid: activation of metabolites to toxic intermediates in man and rat.

Science. 193: 901-903.

107. Nishimura Y., Kurata N., Sakurai E., Yasuhara H. 2004. Inhibitory effect of anti-

tuberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci.

96: 293-300.

108. Ohkawa H, Ohisha N, Yagi K. 1979. Assay of lipid peroxides in animal tissue by

Thiobarbituric acid reaction. Anal Biochem. 5: 351-358.

Bibliography

117

109. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, et al. 2000.

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and

rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis. 4: 256-261.

110. Ortiz de Montellano, P R. 1995. Cytochrome P450. Structure, Mechanism and

Biochemistry. 2nd Ed Plenum Press, New York.

111. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. 2007. Mitochondria, oxidative

stress and cell death. Apoptosis. 12: 913-922.

112. Padma VV, Suja V, Shyamala DCS, Prema. 1998. Hepatoprotective effect of Liv-52

on antitubercular drug-induced hepatotoxicity in rats. Fitoterapia. 69(6): 520-522.

113. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. 1996. Risk factors for

hepatotoxicity from antituberculosis drugs: a case-control study. Thorax. 51: 132-

136.

114. Pandit A, Sachdeva T and Bafna P. 2012. Drug-Induced Hepatotoxicity: A Review

J Appl Pharm Sci. 02 (05): 233-243.

115. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. 2002. Adverse

events associated with pyrazinamide and levofloxacin in the treatment of latent

multidrug-resistant tuberculosis. Can Med Assoc J. 167: 131-136.

116. Parl FF. 2005. Glutathione S-transferase genotypes and cancer risk. Cancer Lett.

221: 123-129.

117. Parthasarathy R, Sarma GR, Janardhanam B, Ramachandran P, Santha

T, Sivasubramanian S. et al. 1986. Hepatic toxicity in South Indian patients during

treatment of tuberculosis with short-course regimens containing isoniazid,

rifampicin and pyrazinamide. Tubercle. 67: 99-108.

118. Pereira RM, Tresoldi AT, Hessel G. 2000. Isoniazid-induced hepatic failure report

of a case. Arq Gastroenteral. 37: 72-75.

Bibliography

118

119. Perez A, Brown HS 3rd, Restrepo BI. 2006. Association between tuberculosis and

diabetes in the Mexican border and non-border regions of Texas. Am J Trop Med

Hyg. 74: 604-611.

120. Peters BS, Carlin E, Weston RJ, Loveless SJ, Sweeney J, Weber J, et al. 1994.

Adverse effects of drugs used in the management of opportunistic infections

associated with HIV infection. Drug Saf. 10: 439-454.

121. Poli G, Albano E, Dianzani MU. 1987. The role of lipid peroxidation in liver

damage. Chem Phys Lipids. 45: 117-142.

122. Pukenyte E, Lescure FX, Rey D, Rabaud C, Hoen B, Chavanet P, et al. 2007.

Incidence of and risk factors for severe liver toxicity in HIV-infected patients on

anti-tuberculosis treatment. Int J Tuberc Lung Dis. 11: 78-84.

123. Purohit SD, Gupta PR, Sharma TN, Gupta DN, Chawla MP. 1983. Rifampicin and

hepatotoxicity. Indian J Tuberc. 30: 107-109.

124. Quemard A, Sacchettini JC, Dessen A, Vilchez C, Bittman R, Jacobs WR, et al.

1995. Enzymatic characterization of the target for isoniazid in Mycobacterium

tuberculosis. Biochemistry. 34(26): 8235-8241.

125. Rebbeck TR. 1997. Molecular epidemiology of the human glutathione S-transferase

genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol

Biomarkers Prev. 6: 733-743.

126. Restrepo BI. 2007. Convergence of the tuberculosis and diabetes epidemics: renewal

of old acquaintances. Clinical Infectious Diseases. 45 (4): 436-438.

127. Rook GA, Hernamndez-Pando R. 1996. The pathogenesis of tuberculosis. Annu Rev

Microbiol. 50: 258-284.

128. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, et al. 2001.

Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with

Bibliography

119

glutathione S-transferase M1 ‘null’ mutation. J Gastroenterol Hepatol. 16: 1033-

1037.

129. Roy PD, Majumder M, Roy B. 2008. Pharmacogenomics of anti-TB drugs-related

hepatotoxicity. Pharmacogenomics. 9(3): 311-321.

130. Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. 1986. Rifampin-

induced release of hydrazine from isoniazid: a possible cause of hepatitis during

treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev

Respir Dis. 133: 1072-1075.

131. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. 2006.

On the behalf of ATS (American Thoracic Society). Hepatotoxicity of

Antituberculosis Therapy. Am J Respir Crit Care Med. 174: 935-952.

132. Schaberg T, Rebhan K, Lode H. 1996. Risk factors for side-effects of isoniazid

rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur

Respir J. 9: 2026-2030.

133. Scharer L, Smith JP. 1969. Serum transaminase elevations and other hepatic

abnormalities in patients receiving isoniazid. Ann Intern Med. 71: 1113-1120.

134. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding

pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug

pyrazinamide in tubercle bacillus. Nat Med. 2: 662-667.

135. Scott JT. 1991. Drug-induced gout. Baillieres Clin Rheumatol. 5: 39-60.

136. Segall L, Covic A. 2010. Diagnosis of tuberculosis in dialysis patients: current

strategy. Clin J Am Soc Nephrol. 5 (6): 1114-1122.

Bibliography

120

137. Selvakumar N, Rahman F, Rajasekaran S, Narayanan PR, Thomas RF. 2002.

Inefficiency of 0.3% Carbol Fuchsin in Ziehl-Neelsen Staining for Detecting Acid-

Fast Bacilli. J Clin Microbiol. 40(8): 3041–3043.

138. Sen S, Chakraborty R, Sridhar C, Reddy YSR, De B. 2010. Free radicals,

antioxidants, disease and phytomedicines: current status and future prospect. Int J

Pharm Sci Review Res. 3: 91-100.

139. Shakya R, Rao BS, Shrestha B. 2006. Evaluation of risk factors for anti tuberculosis

drug induced hepatotoxicity in Nepalese population. Kathmandu Univ J Sci Eng

Technol. 2: 1-8.

140. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. 2005. Evaluation

of patient-related factors associated with causality, preventability, predictability and

severity of hepatotoxicity during antituberculosis [correction of antituberclosis]

treatment. Pharmacol Res. 51: 353-358.

141. Sharma A, Chakraborti KK, Handa SS. 1991. Anti-hepatotoxic activity of some

Indian herbal formulations as compared to silymarin. Fitoterapia. 62: 229-235.

142. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. 2002. Evaluation of

clinical and immunogenetic risk factors for the development of hepatotoxicity during

antituberculosis treatment. Am J Respir Crit Care Med. 166: 916-919.

143. Sheehan D, Meade G, Foley VM, Dowd CA. 2001. Structure, function and evolution

of glutathione transferases: implications for classification of non-mammalian

members of an ancient enzyme superfamily. Biochem J. 360: 1-16.

144. Sheweita SA. 2000. Drug-Metabolizing Enzymes: Mechanisms and Functions,

Current Drug Metabolism. 1: 107-132.

145. Singh J, Garg PK, Tandon R, 1996. Hepatotoxicity due to anti-TB therapy, Clinical

profile and reintroduction of the therapy. J Clin Gastroenterol. 22: 211-214.

Bibliography

121

146. Singla R, Sharma SK, Mohan A, Makharia G, Sreenivas V, Jha B, et al. 2010. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 132: 81-86.

147. Sistanizad M, Azizi E, Khalili, H, Hajiabdolbaghi M, Gholami K and Mahjub R.

2011. Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis

Patients: Role of Isoniazid Metabolic Polymorphism. Iranian J Pharmaceutical

Research. 10 (3): 633-639.

148. Slater TF. 1985. Free radical mechanism in tissue injury. Biochem Journal. 222: 1-

15.

149. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC.

1991. Treatment of tuberculosis in patients with advanced human immunodeficiency

virus infection. N Engl J Med. 324: 289-294.

150. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. 1997. A

simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by

phenotyping with isoniazid. J Med Genet. 34: 758-760.

151. Snider DE, Long MW, Cross FS, Farer LS. 1984. Six months isoniazid and

rifampicin therapy for pulmonary tuberculosis: report of a United States Public

Health Service cooperative trial. Am Rev Respir Dis. 129: 573-579.

152. Sodhi CP, Rana S, Metha S, Vaiphei K, Goel RC, Metha SK. 1997. Study of

oxidative stress in rifampin induced hepatic injury in growing rats with and without

protein energy malnutrition. Hum Exp Toxicol. 16: 315-321.

153. Sodhi CP, Rana SV, Metha SK, Vaiphei K, Attri S, Thakur S, et al. 1996. Study of

oxidative stress in isoniazid induced hepatic injury in young rats with and without

protein energy malnutrition. J Biochem Toxicol. 11: 139-146.

Bibliography

122

154. Solangi GA, Zuberi BF, Shaikh S, Shaikh WM. 2004. Pyrazinamide-induced

hyperuricemia in patients taking anti-tuberculosis therapy. J Coll Physicians Surg

(Pak). 14: 136-138.

155. Steele MA, Burk RF, DesPrez RM. 1991. Toxic hepatitis with isoniazid and

rifampin: a meta-analysis. Chest. 99: 465-471.

156. Stevenson CR, Forouhi NG, Roglic G, Williams BG, Lauer JA, Dye C, et al. 2007.

DM and tuberculosis: the impact of the DM epidemic on tuberculosis incidence.

BMC Public Health. 7:1-8.

157. Strange RC, Jones PW, Fryer AA. 2000. Glutathione S-transferase: genetics and role

in toxicology. Toxicol Lett. 112-113: 357-363.

158. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. 2001. Glutathione-S-

transferase family of enzymes. Mutat Res. 482: 21-26.

159. Sun F, Chen Y, Xiang Y, Zhan S. 2008. Drug-metabolizing enzyme polymorphisms

and predisposition to anti-tuberculosis drug induced liver injury: a meta-analysis. Int

J Tuberc Lung Dis. 12: 994-1002.

160. Sharma SK, Mohan A. 2013. Tuberculosis: From an incurable scourge to a curable

disease - journey over a millennium. Indian J Med Res. 137: 455-493.

161. Takayama K, Kilburn J. 1989. Inhibition of synthesis of arabinogalactan by

ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother. 33: 1493-

1499.

162. Tan KL, Webb GC, Baker RT, Board PG. 1995. Molecular cloning of a cDNA and

chromosomal localization of a human thetaclass glutathione S-transferase gene

(GSTT2) to chromosome 22. Genomics. 25: 381-387.

Bibliography

123

163. Tanaogllu K. 2001. The management of anti-TB drug-induced hepatotoxicity. Int

Union Tuberc Lung Dis. 5: 65-69.

164. Taneja DP, Kaur D. 1990. Study on hepatotoxicity and other side effects of

antituberculosis drugs. J Indian Med Assoc. 88: 278-280.

165. Teixeira RLF, Morato RG, Cabello PH, Muniz LMK, Moreira ASR, Kritski AL, et

al. 2011. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the

occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem

Inst Oswaldo Cruz. 106: 716-724.

166. Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, et al.

1997. The emb operon, a unique gene cluster of Mycobacterium tuberculosis

involved in resistance to ethambutol. Nature Med. 3: 567-570.

167. Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. 1980. Isoniazid

hepatotoxicity: the relationship between covalent binding and metabolism in vivo. J

Pharmacol Exp Ther. 213: 364-369.

168. Timbrell JA, Scales MD, Streeter AJ. 1982. Studies on hydrazine hepatotoxicity. 2.

Biochemical findings. J Toxicol Environ Health. 10: 955-968.

169. Tomasi, A, Billing, S, Garner, A, Slater, TF, Albano E. 1983. The metabolism of

halothane by hepatocytes: a comparison between free radical spin trapping and lipid

peroxidation in relation to cell damage. Chem Biol Interact. 46: 353-368.

170. Tost JR, Vidal R, Cayla J, Diaz-Cabanela D, Jimenez A, Broquetas JM. 2005.

Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis.

9: 534-540.

171. Tostmann A, Boeree MJ, Aarnoutse RE, Lange WCM, Vander Ven AJ, Dekhuijzen

R. 2008. Anti-tuberculosis drug-induced hepatotoxicity: Concise up-to-date review.

J Gastroenterol Hepatol. 23: 192-202.

Bibliography

124

172. Tripathi K, Tripathi PC, Nema S , Shrivastava AK, , Dwiwedi K, Dhanvijay AK.

2014. Modified Petroff’s Method: an Excellent Simplified Decontamination

Technique in Comparison with Petroff’s Method. Int Jof Recent Trends in Science

And Technology, 10 (3): 461-464.

173. Tsai RK, Lee YH. 1997. Reversibility of ethambutol optic neuro-pathy. J Ocul

Pharmacol Ther. 13: 473-477.

174. Tsutsumi M, Takada A, Wang JS. 1994. Genetic polymorphism of cytochrome P-

450 2E1 related to the development of alcoholic liver disease. Gastroenterology.

107: 1430-1435.

175. Turktas H, Unsal M, Tulek N, Oruc O. 1994. Hepatotoxicity of antituberculosis

therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tubercle Lung

Dis. 75: 58-60.

176. Udomsinprasert R, Pongjaroenkit S, Wongsantichon J, Oakley AJ, Prapanthadara

LA, Wilce MC, et al. 2005. Identification, characterization and structure of a new

Delta class glutathione transferase isoenzyme. Biochem J. 388: 763-771.

177. Umeno M, McBride OW, Yang CS, Gelboin HV, Gonzalez FJ. 1988. Human

ethanol-inducible P450IIE1: complete gene sequence, promoter characterization,

chromosome mapping, and cDNA-directed expression. Biochemistry. 27: 9006-

9013.

178. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. 1998.

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the

human immunodeficiency virus. Am J Respir Crit Care Med. 157: 1871-1876.

179. van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, et al. 2010.

Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV

and COPD. Eur Respir J. 35(1): 27-33.

Bibliography

125

180. Villor AF, Sopena B, Villor JF. 2004. The influence of risk factors on the severity of

antituberculosis drug induced hepatotoxicity. Int J Tuberc Lung Dis. 8: 1499-1505.

181. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, et al.

2006. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for

latent tuberculosis. Eur J Clin Pharmacol. 62: 423-429.

182. Wade MM and Zhang Y. 2004. Mechanisms of drug resistance in Mycobacterium

tuberculosis. Front Biosci. 9: 975-994.

183. Wang T, Yu HT, Wang W, Pan YY, He LX, Wang ZY. 2010. Genetic

Polymorphisms of Cytochrome P450 and Glutathione S-transferase Associated with

Antituberculosis Druginduced Hepatotoxicity in Chinese Tuberculosis Patients. The

J Int Med Res. 38: 977-986.

184. Weber WW, Hein DW, Litwin A, Lower GM Jr. 1983. Relationship of acetylator

status to isoniazid toxicity, lupus erythematosus, and bladder cancer. J Fed Proc. 42:

3086-3097.

185. Wen X, Wang JS, Neuvonen PJ, Backman JT. 2002. Isoniazid is a mechanism-based

inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver

microsomes. Eur J Clin Pharmacol. 57: 799-804.

186. WHO Report. 2002. Global Tuberculosis Control. Epidemiology, Stratetgy and

Financing. Geneva: World Health Organisation.

187. WHO Report. 2007. Global tuberculosis control: surveillance, planning, financing.

Geneva: World Health Organization.

188. WHO Report. 2010. Global Tuberculosis Control. Epidemiology, Stratetgy and

Financing. Geneva: World Health Organization.

189. WHO Report. 2012. Global Tuberculosis Control. Epidemiology, Stratetgy and

Financing. Geneva: World Health Organization.

Bibliography

126

190. Wild S, Sicree R, Roglic G, King H, Green A. 2004. Global prevalence of diabetes:

Estimates for the year 200 and projections for 2030. Diabetes Care. 27: 1047-1053.

191. Wolucka BA, McNeil MR, de Hoffmann E, Chojnacki T, Brennan PJ. 1994.

Recognition of the lipid intermediate for arabinogalactan/arabinomannan

biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. J

Biol Chem. 269: 23328-23335.

192. Wong WM, Wu PC, Yuen MF Cheng CC, Yew WW, Wong PC, et al. 2000.

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection.

Hepatology. 31: 201-206.

193. Woodward KN, Timbrell JA. 1984. Acetylhidrazine hepatotoxicity: the role of

covalent binding. Toxicology. 30: 65-74.

194. Wu SS, Chao CS, Vargas JH, Sharp HL, Martin MG, McDiarmid SV, et al. 2007.

Isoniazid-related hepatic failure in children: a survey of liver transplantation

centers. Transplantation. 84: 173-179.

195. Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, et al. 1990. Isoniazid-

rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology. 98: 502-504.

196. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. 2003. Incidence

of serious side effects from first-line antituberculosis drugs among patients treated

for active tuberculosis. Am J Respir Crit Care Med. 167: 1472-1477.

197. Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L, et al. 2008.

Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive

and Negative Patients. PLoS ONE. 3: 1-5.

198. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. 2005. High

hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.

Eur Respir J. 26: 462-464.

Bibliography

127

199. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ.

1995. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and

susceptibility to hepatocellular carcinoma. Gastroenterology.109: 1266-1273.

200. Yue J, Peng RX, Yang J, Kong R, Liu J. 2004. CYP2E1 mediated isoniazid-induced

hepatotoxicity in rats. Acta Pharmacologica Sinica. 25: 699-704.

201. Zellweger JP. 2002. Tuberculosis in households of index patients: is there another

way to control tuberculosis. Int J Tuberc Lung Dis. 6: 181-182.

202. Zhang Y, Scorpio A, Nikaido H, Sun Z. 1999. Role of acid pH and deficient efflux

of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to

pyrazinamide. J Bacteriol. 181: 2044-2049.

203. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. 2003. Mode of action of

pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and

energetics by pyrazinoic acid. J Antimicrob Chemother. 52: 790-795.

204. Zhang Y, Heym B, Allen B, Young D, Cole S. 1992. The catalase-peroxidase gene

and isoniazid resistance of Mycobacterium tuberculosis. Nature. 358(6387): 591-

593.

205. Zimmerman HJ. 1999. Hepatic injury from the treatment of infectious and parasitic

diseases. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other

chemicals on the liver. 2nd ed. Philadelphia: Lippincott. 589-637.